Physician profile
Eric Braun
NPI 1831501634
$1,861.10
in general payments reported to CMS, 2019-2025
25 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $96.70 · 2021: $107 · 2022: $44.14 · 2023: $150 · 2024: $258 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $339.60 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $234.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $198.51 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $168.48 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $160.70 | 2019-2025 | Prolia, Evenity, Otezla |
| Allergan, INC. | $109.51 | 2019-2020 | |
| Amarin Pharma, INC. | $71.51 | 2019 | |
| Abbvie INC. | $65.19 | 2019-2024 | Vraylar |
| Arcutis Biotherapeutics, INC. | $58.14 | 2025 | Zoryve |
| Astellas Pharma US INC | $56.12 | 2019 | |
| Shire North American Group INC | $53.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $40.66 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $35.37 | 2021 | |
| Merck Sharp & Dohme LLC | $33.17 | 2019-2024 | Proquad, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $31.06 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $30.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.23 | 2019 | |
| Corium, LLC | $22.53 | 2022 | |
| Dexcom, INC. | $22.09 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $20.63 | 2021 | |
| Abbott Laboratories | $19.56 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.67 | 2019 | |
| Lilly USA, LLC | $12.61 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Braun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.